Skip to main content

Table 1 Patients’ characteristics

From: Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy

Characteristics High-dose-rate brachytherapy (n = 10) Stereotactic body radiation therapy (n = 18) p value p value
Primary treatment (%) Recurrence (%) Primary treatment (%) Recurrence (%) Primary Recurrence
Age (years, median, IQR) 63 (58–68) 69 (65–77) 62 (58–66) 69 (64–75) 0.87 0.85
PSA at the time of treatment (ng/mL, median, IQR) 26 (8.6–47) 4.37 (2.01–4.76) 6.6 (5.7–9.2) 4.5 (3.0–6.3) 0.0046 0.43
Initial T stage   -   - 0.005  
 T1c 2 (20.0)   12 (66.7)    
 T2a 2 (20.0)   2 (11.1)    
 T3 6 (60.0)   2 (11.1)    
 Not evaluated -   2 (11.1)    
Initial Gleason sum      0.04 0.71
 Gleason 6 or less 2 (20.0) 1 (10.0) 13 (72.2) 2 (11.1)   
 Gleason 7 4 (40.0) 2 (20.0) 4 (22.2) 2 (11.1)   
 Gleason 8 4 (40.0) 1 (10.0) 1 (5.6) 1 (5.6)   
 Gleason 9 - 2 (20.0) - 2 (11.1)   
 Not evaluated - 4 (40.0) - 11 (61.1)   
D’Amico risk group      0.006  
 Low 1 (10.0) - 10 (55.6) -   
 Intermediate 2 (20.0)   5 (27.8)    
 High 7 (70.0)   2 (11.1)    
 Not evaluated -   1 (5.6)    
Tumor localization      0.21 0.019
 Apex - 1 (10.0) -    
 Median - - 2 (11.1) 2 (11.1)   
 Basis - 3 (30.0) 1 (5.6) 1 (5.6)   
 Seminal vesical 1 (10.0) - - 7 (38.9)   
 More than 1 location 1 (10.0) 6 (60.0) 3 (16.7) 3 (16.7)   
 Not evaluated 8 (80.0) 1 (10.0) 12 (66.7) 4 (22.2)   
Initial ADT duration   -   - 0.0031  
 Short (6 months) 2 (20.0)   7 (38.9)    
 Long (24–36 months) 5 (50.0)   1 (5.6)    
 No ADT 3 (30.0)   10 (55.6)    
ADT at recurrence -   -    0.05
 Yes   2 (20.0)   10 (55.6)   
 No   8 (80.0)   8 (44.4)   
ADT duration (months, median, IQR) - 63.5 (48–79) - 15 (6–21)   0.028
Initial radiation modality   -   - <0.001  
 LDR brachytherapy 1 (10.0)   15 (83.3)    
 EBRT w/o pelvic radiation 5 (50.0)   3 (16.7)-    
 EBRT with pelvic radiation 4 (40.0)      
Prostate volume (cc, median, IQR) 33.5 (32–35) 35 (20–50) 35 (25–44.5) 26 (22.5–28.5) 0.78 0.59
PSA nadir (ng/mL, median, IQR) 0.065 (0.01–0.2) 0.66 (0.23–1.13) 0.58 (0.34–1.05) 0.89 (0.29–1.4) 0.0034 0.97
Time to PSA nadir (months, median, IQR) 21 (16–30) 6 (5–8) 28 (11–35) 7.5 (4.5–10) 0.79 0.89
Time to biological recurrence (months, median, IQR) 69 (55–85) 13 (10–26) 49 (37–70) 5.5 (4–6) 0.11 0.0347
Time to salvage treatment (months, median, IQR) 86.5 (66–108) - 77 (64–92) - 0.26  
  1. Note: PSA prostate specific antigen, ADT androgen deprivation therapy, IQR interquartile range, LDR low-dose-rate, EBRT external beam radiotherapy